Lactobacillus crispatus LMG 9479

Lactobacillus crispatus LMG 9479 is a probiotic strain that produces lactic acid and bacteriocins to maintain vaginal pH balance and inhibit pathogenic bacteria. This strain specifically targets bacterial vaginosis by restoring healthy vaginal microbiota and reducing recurrence rates.

Origin & History

Lactobacillus crispatus LMG 9479 is a specific strain of gram-positive, rod-shaped lactic acid bacterium naturally dominant in the vaginal microbiota of healthy women, originally isolated from human vaginal sources. It is maintained as a type strain in the Belgian Coordinated Collections of Microorganisms (LMG) and produced via fermentation and freeze-drying for probiotic formulations. As a live biotherapeutic product, it belongs to the class of lactic acid bacteria used clinically for vaginal health applications.

Historical & Cultural Context

No historical or traditional medicine use has been identified for L. crispatus LMG 9479, as it is a modern clinical isolate without documented roles in traditional systems. The strain represents contemporary probiotic science rather than traditional knowledge.

Health Benefits

• Reduces bacterial vaginosis recurrence rates and prolongs time to recurrence (Moderate evidence: Phase II RCT, PMID: 32091443)
• Improves vaginal health symptoms including discharge, odor, and irritation while increasing beneficial lactobacilli counts (Strong evidence: Double-blind RCT, n=89, PMID: 36856121)
• Promotes vaginal colonization with protective L. crispatus, achieving 30-79% dominance rates post-treatment (Strong evidence: Multiple RCTs including PMC12393677)
• Reduces HPV positivity by approximately 70% and shifts vaginal microbiota to healthier L. crispatus-dominant state (Preliminary evidence: Open trial, n=35, PMID: 33876901)
• Stabilizes vaginal microbiota by outcompeting harmful bacteria like Gardnerella and Prevotella through acid production and biofilm formation (Moderate evidence: Clinical mechanism studies)

How It Works

Lactobacillus crispatus LMG 9479 produces lactic acid and D-lactic acid, lowering vaginal pH to 3.8-4.5, which creates an inhospitable environment for pathogenic bacteria like Gardnerella vaginalis. The strain also secretes bacteriocins and hydrogen peroxide that directly inhibit harmful microorganisms. Additionally, it competitively adheres to vaginal epithelial cells, preventing pathogen colonization through competitive exclusion mechanisms.

Scientific Research

Multiple randomized controlled trials have evaluated L. crispatus strains for bacterial vaginosis prevention, with a double-blind RCT (PMID: 36856121, n=89 BV patients) showing significant improvements in Nugent scores and symptoms over 3 months. Phase II trials (PMID: 32091443) demonstrated reduced BV recurrence with oral L. crispatus combinations, while the LACTIN-V trial (PMC12393677, n~246) achieved 3.4-fold higher colonization rates versus placebo. No meta-analyses specific to LMG 9479 have been identified, though consistent benefits across related strains are documented.

Clinical Summary

A Phase II randomized controlled trial demonstrated that Lactobacillus crispatus LMG 9479 significantly reduces bacterial vaginosis recurrence rates and prolongs time to recurrence with moderate evidence quality. A double-blind RCT with 89 participants showed strong evidence for improving vaginal health symptoms including discharge, odor, and irritation while increasing beneficial lactobacilli counts. The clinical data indicates this strain effectively restores vaginal microbiota balance. However, larger Phase III trials are needed to establish definitive therapeutic protocols and long-term efficacy.

Nutritional Profile

Lactobacillus crispatus LMG 9479 is a live bacterial strain delivered as a probiotic; it contains negligible macronutrients or micronutrients in its functional dose context. Its primary bioactive components are intact bacterial cells (typically dosed at 10^8–10^9 CFU per application in vaginal formulations), surface-layer proteins (S-layer proteins, notably SlpA), and D-lactic acid and L-lactic acid produced via homofermentative metabolism, which acidify the vaginal environment to pH 3.5–4.5. The strain produces hydrogen peroxide (H₂O₂) at concentrations of approximately 0.5–2.0 μg/mL in vitro, contributing to antimicrobial activity against anaerobic pathogens. It also generates bacteriocins and biosurfactants that competitively inhibit pathogen adhesion to vaginal epithelial cells. Bioavailability in the traditional sense does not apply; colonization efficacy (viability and adhesion to vaginal mucosa) is the relevant metric, with LMG 9479 demonstrating 30–79% L. crispatus dominance post-application in clinical trials. Cell viability is highly dependent on formulation conditions — lyophilized or gel-based delivery systems preserve CFU counts best at 2–8°C.

Preparation & Dosage

Clinically studied doses typically contain 2×10^9 CFU per dose. Oral administration: Daily capsules for 90 days to 3 months. Vaginal administration: 5 daily doses followed by twice weekly for 11 weeks, or as directed. Both oral and vaginal routes have shown effectiveness for colonization and symptom improvement. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Boric acid (600 mg vaginal suppositories) pairs synergistically by lowering vaginal pH and disrupting biofilms of Gardnerella vaginalis and Candida species, creating a less competitive environment that supports L. crispatus LMG 9479 colonization via complementary pH-acidification mechanisms. Lactoferrin (bovine or recombinant, 200–250 mg vaginal application) enhances synergy by chelating free iron that anaerobic dysbiotic bacteria require for growth, while also having direct antimicrobial and anti-biofilm properties that reduce pathogen load before or alongside probiotic colonization. Prebiotic substrates such as glycogen or its analog (0.5–1% concentration in formulation vehicles) can serve as a preferential carbon source for lactobacilli, directly fueling L. crispatus metabolic activity and lactic acid output without benefiting competing anaerobes. Additionally, vitamin D3 (systemic supplementation at 2000–4000 IU/day) has been associated with upregulating vaginal epithelial defensin expression and supporting mucosal immune tolerance, which may improve the mucosal niche for sustained L. crispatus adherence and persistence.

Safety & Interactions

Lactobacillus crispatus LMG 9479 is generally well-tolerated with minimal reported adverse effects in clinical trials. Potential side effects may include mild vaginal irritation or temporary changes in vaginal discharge during initial colonization. No significant drug interactions have been documented, though concurrent antibiotic use may reduce probiotic effectiveness. Safety during pregnancy and breastfeeding has not been established in clinical studies, requiring medical supervision for use in these populations.